An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

Summary

ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).

Timeline

Start

2026-03-25

Primary completion

2029-03

Completion

2029-03

Drugs

Indications